Kailera Therapeutics, Inc. (KLRA) News
Track canonical SquawkNews coverage tagged to KLRA, Kailera Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Kailera Therapeutics, Inc. (KLRA) Completes Enrollment in Three Phase 3 Obesity Trials
Kailera completed enrollment in all three KaiNETIC global Phase 3 trials of ribupatide injection for obesity/overweight. Topline data from KaiNETIC-1, -2, and -3 are expected in mid-2028.Material DetailsContext by AI Ana
NEWS | Sep 30, 2026, 11:09 AM UTC
L
Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics Inc NASDAQ:KLRA
NEWS | Sep 30, 2026, 11:02 AM UTC
L
KLRA - Kailera Therapeutics to Participate in September Investor Conferences
KLRA - Kailera Therapeutics to Participate in September Investor Conferences
NEWS | Sep 16, 2026, 11:00 AM UTC
L
KLRA Reports Q2 2026 Financial Results
KLRA reports second quarter 2026 financial results and provides business updates
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Therapeutics Inc. (NASDAQ: KLRA ) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China. Investors
RATES | Jul 07, 2026, 04:45 PM UTC